LOSE-AF: Can Weight Loss Help Patients With Atrial Fibrillation?
NCT ID: NCT03713775
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
180 participants
INTERVENTIONAL
2018-11-14
2024-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim The aim of this study is to investigate whether, in older overweight/obese AF patients, referral to a weight loss programme with meal replacement \& behavioral support can reduce AF-recurrences and improve physical performance compared to usual care.
Study design Parallel-group, open-label, multi-centre randomised controlled trial. Elderly individuals (60-85 years) with persistent AF and elevated body mass index (BMI; ≥ 27 kg/m2) will be recruited. Participants will be randomly allocated (1:1) to (a) referral to a meal replacement programme with behavioral support (intervention) or (b) usual care (control) for 32-to-36 weeks. The primary endpoints are AF recurrence and physical performance test (PPT) score. Participants randomised to the study intervention will be referred to a commercial provider (CP) providing the intervention. The co-primary endpoints of AF recurrence \& PPT score will be analysed irrespective of compliance during the scheduled treatment period following an intention-to-treat principle.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The incidence and prevalence of AF are closely linked to increasing age and excess weight. On one hand, advanced age is the most important non-modifiable risk factor for AF and the corollary is that AF is associated with frailty and impaired physical function. Meanwhile, excess weight is of particular interest as results from four large community-based European studies clearly demonstrated that elevated body mass index (BMI) is the strongest modifiable risk factor for incident AF. A large-scale observational cohort study reported a 4% increase in AF-risk per 1-unit increase in body mass index (BMI) after adjustment for cardiovascular risk factors and interim myocardial infarction or heart failure. Moreover, a recent Mendelian randomization study confirmed a causal relationship between increased BMI and incident AF. The precise mechanisms by which obesity increases the risk of development and maintenance of AF are incompletely understood; potential contributors include left atrial (LA) enlargement, left ventricular (LV) hypertrophy, diastolic dysfunction, altered cardiac energetics, and inflammatory/oxidative signalling from the epicardial adipose tissue.
Very low calorie diets, providing less than 800 kcal/d have been used for many years as highly effective methods for inducing weight loss, leading to consistent reductions in visceral fat and overall adiposity. A systematic review showed weight loss at 1 year of 8-14 kg, which was 4.3 kg (95% CI: 1.1 kg, 7.4 kg) greater than the comparator interventions. The historical limitation of very low calorie diets has historically been long-term effectiveness, and there has been growing interest in the use of total meal replacement sachets as part of a wider behavioural programme. This includes individualised one-to-one counselling to motivate and encourage adherence to the diet, as well as support to establish a healthy eating plan when individuals reintroduce food. Results from DiRECT (a cluster-randomised trial assessing a meal replacement programme in patients with type II diabetes) were published recently in The Lancet: the intervention arm reached an average weight loss of 10 kg at 1 year with 45% of individuals achieving complete remission of type II diabetes, which is also a relevant risk factor for AF. Preliminary data suggest that such a programme proved highly effective in reducing AF symptoms in a relatively young group of AF patients where the diet resulted in significant weight loss (\>10kg) sustained to 15 months. However, it remains unclear whether the beneficial effects of weight loss translate in (a) reducing AF recurrences and (b) whether they also extend to the more typical elderly patient population with AF, as reversing cardiac remodelling may prove more difficult in aged hearts. Additionally, the balance between beneficial and detrimental effects of weight loss in the elderly may be dependent on preservation of muscle strength.
The aim of this study is to investigate whether, in older overweight/obese AF patients, referral to a weight loss programme with meal replacement \& behavioral support can reduce AF-recurrences and improve physical performance compared to usual care.
This is a parallel-group, open-label, randomized controlled study to determine whether substantial weight reduction through referral to a weight loss programme with meal replacement \& behavioral support in older patients who are overweight/obese with persistent AF can reduce AF recurrences and symptoms and improve the adverse cardiometabolic profile and physical performance. The expected duration of such programme is approximately 8 months, with a total of two study visits (at baseline and at 8 months). AF-related symptoms (primary endpoint) are assessed at baseline and at approximately 8 months after the commencement of the intervention using the AFSS symptom score.
Elderly individuals (60-85 years) with elevated BMI (≥27 kg/m2), who are scheduled for a DCCV with a diagnosis of persistent AF will be recruited. Participants will be randomised (1:1) to (a) weight loss programme for a total of \~8 months (intervention) or (b) usual care; i.e., nurse-based consultation and supporting written material (control). All participants will undergo a baseline visit (prior to randomisation) and a follow-up visit at \~8 months. Both study visits will include a physical performance test (PPT), AF symptom assessment using the AFSS score, anthropometric measurements, quality of life assessment, Patient Health-Resource Use Questionnaire (PRUQ), MR scan, and blood sample collection. Additionally, prolonged ECG monitoring, and patient reported outcome measures (PROMs) will also be acquired at the 8-month visit. Finally, at approximately 4 months patients will be asked to complete interim questionnaires (including PRUQ, PROMs, Quality of Life) by post/telephone.
In the LOSE-AF trial, the intervention is at very low risk of adverse events and no Trial Steering Committee or Clinical Trial Authorization is required. The study will be coordinated by the Trial Management Committee (TMC), consisting of at least one core study investigator (a medically qualified clinician), and the research nurse. The TMC will be responsible for the day-to-day management of the trial and will meet regularly.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Meal Replacement Weight Loss Programme
The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
Meal Replacement Weight Loss Programme
The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
Usual Care
Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
Usual Care
Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meal Replacement Weight Loss Programme
The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
Usual Care
Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index ≥27 kg/m2
Exclusion Criteria
* Learning difficulties or unable to understand English
* Participation in another research trial involving an investigational product or weight loss programme in the prior 3 months
* Current treatment with anti-obesity drugs
* Uncontrolled endocrine disorders
* Diabetes requiring insulin
* Active gout or history of recurrent gout
* Ongoing gallbladder disease
* Serious underlying medical or psychiatric disorder; e.g., known cancer or any other significant disease affecting short-term life expectancy; severe valvular disease, myocardial infarction or stroke within the previous 6 months; severe heart failure; eating disorder or purging behaviour; severe psychotic disorder requiring hospitalisation or supervised care, active liver disease (except non-alcoholic fatty liver disease).
* Unintentional weight loss of more than 5 kg within the prior 6 months
* Gastrointestinal malabsorption
* Unstable INR (persistently \<2 for \>14 days) or supra-therapeutic levels with concomitant bleeding or requiring hospitalisation
* Substance abuse
* Taking varenicline (smoking cessation medication)
* Chronic renal failure of stage 4 or 5
* Porphyria
60 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara Casadei, MD DPhil
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oxford Centre for Magnetic Resonance (OCMR)
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marcin Grzegorczyk
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
242939
Identifier Type: OTHER
Identifier Source: secondary_id
PID13511-SP001-AC002
Identifier Type: -
Identifier Source: org_study_id